Clopidogrel Response Variability and Future Therapies
2006; Lippincott Williams & Wilkins; Volume: 114; Issue: 22 Linguagem: Inglês
10.1161/circulationaha.106.643171
ISSN1524-4539
AutoresMichelle L. O’Donoghue, Stephen D. Wiviott,
Tópico(s)Acute Myocardial Infarction Research
ResumoHomeCirculationVol. 114, No. 22Clopidogrel Response Variability and Future Therapies Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBClopidogrel Response Variability and Future TherapiesClopidogrel: Does One Size Fit All? Michelle O'Donoghue and Stephen D. Wiviott Michelle O'DonoghueMichelle O'Donoghue From TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Mass. and Stephen D. WiviottStephen D. Wiviott From TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Mass. Originally published28 Nov 2006https://doi.org/10.1161/CIRCULATIONAHA.106.643171Circulation. 2006;114:e600–e606Case Presentation: A 75-year-old woman presents to the hospital with a non–ST-elevation myocardial infarction (MI) and is found to have a subtotal occlusion of the proximal left anterior descending coronary artery. A drug-eluting stent is successfully deployed without complication, and the patient is given a 300-mg loading dose of clopidogrel. She is started on a treatment regimen that includes aspirin 325 mg daily and clopidogrel 75 mg daily. On hospital day 4, she develops recurrent chest pain and is found to have ST-segment elevation on ECG. She is taken to coronary angiography, where she is found to have an occlusive thrombus within a well-deployed stent. After percutaneous coronary intervention (PCI), how should this patient be managed?BackgroundPlatelets play a central role in initiating and propagating pathological thrombosis after spontaneous or mechanical plaque rupture. Antiplatelet therapies, including aspirin and thienopyridines, are key components of pharmacotherapy in acute coronary syndromes (ACS) and PCI.1,2 As monotherapy, treatment with clopidogrel modestly reduces cardiovascular (CV) events in patients with established atherosclerotic disease compared with aspirin treatment.3 When combined with aspirin, clopidogrel provides additive reduction in the risk of ischemic events in patients with non–ST-elevation ACS and in patients undergoing PCI.4,5 In addition, clopidogrel helps to maintain infarct-related artery patency and clinical outcomes in patients with ST-elevation MI receiving fibrinolytic therapy.6,7Clopidogrel, a prodrug, relies on cytochrome P450–dependent pathways to form its active metabolite and inhibits platelet aggregation through irreversible blockade of the platelet P2Y12 receptor (Figure 1). When a 300-mg loading dose is used, clopidogrel requires at least 4 to 6 hours to achieve its maximal effect.8 Analyses from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial suggest that clopidogrel pretreatment 6 to 15 hours before PCI is necessary to significantly reduce CV events.5,9 Clinicians often are reluctant, however, to administer clopidogrel before angiography because of concerns about bleeding in patients who require coronary artery bypass graft surgery within 5 days of receiving the drug.10Download figureDownload PowerPointFigure 1. ADP receptors on the platelet cell surface. VASP indicates vasodilator-stimulated phosphoprotein; PLC, phospholipase C.Response VariabilityDespite improved outcomes with modern-day therapies, ≈8% to 10% of patients experience a recurrent CV event during the first year after ACS.4,5 In addition, ≈1% to 3% have a subacute stent thrombosis after PCI with potentially catastrophic consequences, including a high risk of early mortality.11Several studies have demonstrated substantial interpatient variability in measures of platelet inhibition after treatment with clopidogrel (Figure 2).12–18 The prevalence of individuals who are deemed to have an inadequate response to clopidogrel varies between 4% and 34%, depending on the method of testing and the definition of "resistence" or "hyporesponsiveness" used in the individual analyses.2 Differences in assays, agonist concentrations, and cut points have contributed to the confusion about the true prevalence of these conditions. As such, there remains no clear consensus on the definition of clopidogrel resistance. Moreover, the question remains whether this phenomenon can in fact be blamed for clinical failures. For this reason, we believe that the term clopidogrel resistance should be limited to those who fail to achieve a desired pharmacological response to drug therapy, rather than patients who experience recurrent ischemic events while on clopidogrel (Figure 3).19Download figureDownload PowerPointFigure 2. Interindividual variability in platelet response to clopidogrel after stenting. Clopidogrel "resistance" was defined as an absolute change in platelet aggregation 300 mg for patients undergoing PCI who need to achieve higher platelet inhibition more rapidly but emphasize that the relative efficacy and safety of this approach remain incompletely defined.2 In addition, a class IIa indication is listed for a 150-mg daily maintenance dose in subjects in whom subacute stent thrombosis may be catastrophic (eg, unprotected left main, bifurcating left main, or last patent coronary vessel) and in whom an IPA <50% is demonstrated, although no particular assay technique is specified.2 The European Society of Cardiology endorsed a 600-mg loading dose of clopidogrel if PCI is performed <6 hours after initial drug administration.43Novel Antiplatelet TherapiesSeveral antiplatelet agents are now in development (Figure 5) and aim to address potential limitations of clopidogrel, including delayed onset of action, moderate levels of platelet inhibition, and interindividual variability. Download figureDownload PowerPointFigure 5. The molecular structures of several P2Y12 inhibitors.PrasugrelPrasugrel (CS-747, LY640315) is a rapid-acting thienopyridine that achieves higher and more consistent levels of platelet inhibition compared with clopidogrel.44–46 Prasugrel, like clopidogrel, requires hepatic metabolism to form its active metabolite and irreversibly inhibits the P2Y12 receptor.47 In a crossover study of healthy volunteers, the IPA was higher and more consistent with a 60-mg loading dose of prasugrel than with 300 mg of clopidogrel.44 The enhanced potency of prasugrel may be explained by differences in drug absorption or metabolism to the active metabolite, because both clopidogrel and prasugrel have similar potency when equivalent molar concentrations of active metabolite are compared ex vivo48; prasugrel achieves 10- to 100-fold higher levels of active metabolite in vivo.49In the Joint Utilization of Medications to Block Platelets Optimally–Thrombolysis in Myocardial Infarction (JUMBO-TIMI 26) trial, prasugrel was found to be well tolerated and to have a safety profile similar to that of clopidogrel when subjects undergoing elective or urgent PCI were treated for up to 30 days.50 Although the study was not powered to examine efficacy, subjects receiving prasugrel tended to have lower rates of adverse CV events, including a lower risk of periprocedural MI or need for revascularization.Enrollment is underway in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel (TRITON)–TIMI 38, a phase III trial studying subjects with ACS undergoing PCI (ClinicalTrials.gov identifier: NCT00097591).51 TRITON-TIMI 38 is the first large trial to help determine whether achieving higher levels of IPA will lead to improved clinical outcomes. In an additional study, the relative potency of prasugrel is being compared with a higher loading dose (600 mg) and maintenance dose (150 mg daily) of clopidogrel by examining measures of platelet function, inflammation, and myocyte necrosis in patients undergoing elective PCI in the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation (PRINCIPLE)–TIMI 44 study (ClinicalTrials.gov identifier: NCT00357968).AZD6140Because genetic and acquired variability in the cytochrome P450–dependent pathways may contribute to clopidogrel response variability, drugs that directly target the P2Y12 receptor without the need for metabolism may have promise. AZD6140 is an orally active, reversible, competitive inhibitor of the P2Y12 receptor.52 The drug is the first in a new class of oral antiplatelet agents known as cyclopentyl triazolopyrimidines. AZD6140 has onset of action within 2 hours in the absence of a loading dose, a short half-life (≈12 hours) that requires twice-daily dosing, and a shorter time for drug offset after discontinuation. Preclinical and phase II studies have demonstrated higher and more consistent levels of platelet inhibition with AZD6140 compared with clopidogrel.53,54The largest clinical experience with AZD6140 to date is the Double-Blind, Double-Dummy, Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140+Acetyl Salicyclic Acid (ASA) Compared With Clopidegrel+ASA in Patients With Non-ST Segment Elevation Acute Coronary Syndromes (DISPERSE-2) trial, which evaluated the safety, tolerability, and antiplatelet effects of AZD6140 in 990 patients with non–ST-elevation ACS.55 Subjects treated with AZD6140 had higher levels of platelet inhibition54 and showed a trend toward lower rates of recurrent MI compared with subjects treated with clopidogrel and with a similar risk of bleeding.55 There were higher rates of dyspnea, hypotension, and nausea in patients randomized to treatment with AZD6140, although rates of drug discontinuation were similar across treatment arms.55 The Platelet Inhibition and Patient Outcomes (PLATO) trial (ClinicalTrials.gov identifier: NCT00391872) will compare the clinical efficacy of AZD6140 to clopidogrel in patients with ACS.CangrelorCangrelor (AR-C69931MX) is a potent, nonthienopyridine P2Y12 receptor antagonist that offers several distinct features, including an intravenous formulation, reversibility, and a short half-life (3 to 5 minutes). Because it does not require metabolism to become active, cangrelor can achieve nearly complete inhibition of ADP-induced platelet aggregation with very rapid onset.56 Because the antiplatelet effects of cangrelor can be completely reversed in 20 to 50 minutes, the compound may offer an advantage for patients who need to achieve rapid platelet inhibition for PCI with the ability for swift reversal (eg, those who may require urgent coronary artery bypass graft).Early-phase testing has demonstrated that cangrelor achieves very high degrees of platelet inhibition with an acceptable safety profile in patients with non–ST-elevation ACS not undergoing PCI.56,57 A pharmacodynamic study of cangrelor in patients undergoing PCI demonstrated a trend toward shorter bleeding times compared with treatment with abciximab.58 Additional evaluation of this agent is being pursued in phase III studies, including the Clinical Trial Comparing Cangrelor to Clopidogrel in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION-PCI: Clinical Trials.gov identifier: NCT00305162) and the Clinical Trial Comparing Treatment With Cangrelor (in Combination With Usual Care) to Usual Care, in Subjects Who Require Percutaneous Coronary Intervertion (CHAMPION-PLATFORM; ClinicalTrials.gov identifier: NCT00385138).ConclusionsDespite a robust and consistent benefit across large clinical trials, a significant interindividual variability in pharmacological response to clopidogrel has been demonstrated; one size does not fit all. Patients with a diminished response to clopidogrel may be at increased risk of adverse events. Current guidelines do not clearly define what actions should be taken for the pharmacological management of patients with stent thrombosis such as the patient described in the opening clinical vignette. A reasoned approach would be to identify potential causes, including mechanical difficulties (incompletely deployed stent or edge dissection) or noncompliance with prescribed antiplatelet therapy. In the absence of these findings, the clinician may consider empirically increasing the dose of clopidogrel to 150 mg daily after PCI; however, the net clinical benefit of such a strategy remains untested. Additional measures include reducing the dose or eliminating medications that may interfere with clopidogrel metabolism. These strategies were adopted in the management of the patient in the opening case of the article, including an increase in the maintenance dose of clopidogrel to 150 mg daily. The patient was subsequently discharged home and at this time has not had any recurrent ischeme events during follow-up.Platelet function testing may prove to be useful to clinicians to guide therapy, but the ideal assay method and values required to reduce clinical events remain undetermined. Several novel antiplatelet therapies may help to address some of the limitations of current therapies and, if approved, may serve as options to help reduce adverse outcomes or as treatment alternatives for patients with an inadequate response to therapy or subacute stent thrombosis.Sources of FundingFunding for studies and substudies conducted by the TIMI Study Group has been provided for the past 2 years by Merck & Co, Inc; Bristol-Myers Squibb Pharmaceutical Research Institute; Sanofi-Aventis; Millennium Pharmaceuticals, Inc; Nuvelo, Inc; AstraZeneca Pharmaceuticals LP; CV Therapeutics, Inc; Inotek Pharmaceuticals Corp; Eli Lilly and Co; Schering-Plough Research Institute; Integrated Therapeutics Corp; Bayer Healthcare LLC; Ortho-Clinical Diagnostics, Inc; Sanofi-Synthelabo Recherche; GlaxoSmithKline; Amgen, Inc; Beckman Coulter, Inc; Biosite Inc; Roche Diagnostics Corp; Roche Diagnostics GmbH; Pfizer, Inc; Accumetrics, Inc; National Institutes of Health; and Novartis Pharmaceuticals.DisclosuresDr O'Donoghue has received research support from Eli Lilly and Daiichi Sankyo. Dr Wiviott has research support from Eli Lilly and Daiichi Sankyo; has served as a consultant for Amgen, Transform Pharmaceuticals, Biogen-Idec, Forrest Laboratories, Sanofi-Adventis, and Molecular Insight; and has received honoraria from Pfizer, Merck, Eli Lilly, Daiichi Sankyo, Sanofi-Aventis, and Accumetrics.FootnotesCorrespondence to Stephen D. Wiviott, MD, TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA 02115. E-mail [email protected] References 1 Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE 3rd, Steward DE, Theroux P, Gibbons RJ, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Smith SC Jr. ACC/AHA guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction–2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 2002; 106: 1893–1900.LinkGoogle Scholar2 Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, Morrison DA, O'Neil WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006; 113: e166–e286.LinkGoogle Scholar3 A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE): CAPRIE Steering Committee. Lancet. 1996; 348: 1329–1339.CrossrefMedlineGoogle Scholar4 Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494–502.CrossrefMedlineGoogle Scholar5 Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002; 288: 2411–2420.CrossrefMedlineGoogle Scholar6 Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005; 352: 1179–1189.CrossrefMedlineGoogle Scholar7 Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005; 366: 1607–1621.CrossrefMedlineGoogle Scholar8 Montalescot G, Sideris M, Meuleman C, Bal-dit-Sollier M, Lellouche N, Steg G, Slama M, Milleron O, Collet J, Henry P, Beygui F, Drouet L. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) Trial. J Am Coll Cardiol. 2006; 48: 931–938.CrossrefMedlineGoogle Scholar9 Steinhubl SR, Darrah S, Brennan D, McErlan E, Berger PB, Topol EJ. Optimal duration of pretreatment with clopidogrel prior to PCI: data from the Credo Trial. Circulation. 2003; 108 (suppl IV): IV-374. Abstract.Google Scholar10 Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, Yusuf S. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) Trial. Circulation. 2004; 110: 1202–1208.LinkGoogle Scholar11 Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ, Carrozza JP Jr, Chauhan MS, Rodriguez O, Kuntz RE. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001; 103: 1967–1971.CrossrefMedlineGoogle Scholar12 Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med. 2002; 252: 233–238.CrossrefMedlineGoogle Scholar13 Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003; 107: 2908–2913.LinkGoogle Scholar14 Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003; 89: 783–787.CrossrefMedlineGoogle Scholar15 Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll RC. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol. 2004; 93: 456–458.CrossrefMedlineGoogle Scholar16 Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004; 109: 3171–3175.LinkGoogle Scholar17 Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005; 45: 246–251.CrossrefMedlineGoogle Scholar18 Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation. 2005; 111: 1153–1159.LinkGoogle Scholar19 Wiviott SD, Antman EM. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation. 2004; 109: 3064–3067.LinkGoogle Scholar20 von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation. 2005; 112: 2946–2950.LinkGoogle Scholar21 Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002; 54: 1271–1294.CrossrefMedlineGoogle Scholar22 Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, Guyer KE, Tait AR, Bates ER. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004; 109: 166–171.LinkGoogle Scholar23 Suh JW, Koo BK, Zhang SY, Park KW, Cho JY, Jang IJ, Lee DS, Sohn DW, Lee MM, Kim HS. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. Can Med Assoc J. 2006; 174: 1715–1722.CrossrefMedlineGoogle Scholar24 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E, Sabate M, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Costa MA, Bass TA, Pignatti PF, Macaya C. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol. 2006; 26: 1681–1683.LinkGoogle Scholar25 Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DG, Guyer KE, Bates ER. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2003; 107: 32–37.LinkGoogle Scholar26 Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, Topol EJ. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation. 2003; 108: 921–924.LinkGoogle Scholar27 Serebruany VL, Midei MG, Malinin AI, Oshrine BR, Lowry DR, Sane DC, Tanguay JF, Steinhubl SR, Berger PB, O'Connor CM, Hennekens CH. Absence of interaction between atorvastatin or other statins and clopidogrel: results from
Referência(s)